Call for action over blood derivative combinations
This article was originally published in Clinica
The European medical devices industry is supporting the European Commission's proposals to amend the Medical Devices Directive so that it covers devices containing blood derivatives. Industry hopes that products, where the device performs the primary function and the blood derivative discharges a secondary action (eg albumin coatings), will fall under the drug/device combination rules of the Medical Devices Directive.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.